Skip to content

Clinical Trial To Compare The Effect Of Ikseer E Shifa and Zolpidem In Patients Of Insomnia

A Randomized Controlled Open Labeled Clinical Trail To Evaluate The Efficacy Of Ikseer E Shifa In Comparison Of Zolpidem In Management Of Primary Insomnia. - PIIS

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112549
Enrollment
30
Registered
2026-06-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G470- Insomnia Health Condition 2: F510- Insomnia not due to a substance orknown physiological condition

Interventions

Intervention1: IKSEER E SHIFA: 01 tablet of 520 mg orally twice a day with 250 ml of milk after meals.IKSEER E SHIFA 520mg Tablet (Containing Asrol,Nishahta gandum,Milk of Sugar,Chalk powder) Control

Sponsors

STATE TAKMEEL UT TIB COLLEGE AND HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient meets DSM-5 criteria for Primary insomina:more than equal to 3 nights/week for more than equal to 3 months. 2.Patients with ISI more than equal to 15 (moderate severe insomnia). 3.Patient who will give consent, willing to avoid new sleep meds/psychotherapy during trial, maintain stable caffeine/alcohol habits and are able to do follow up.

Exclusion criteria

Exclusion criteria: 1. Patients with history of Major psychiatric co-morbidity (MDD with Suicidality, psychosis bipolar). 2. Patients with history of otheir primary sleep disorders: restless legs/ PLMD (Periodic Limb Movement Disorder), circadian rhythm disorders (due to jet lag or night or rotating shifts), parasomnias needing treatment. 3. Patients with history of current use of hypnotics, benzodiazepines, antipsychotics, sedating antihistamines within 04 weeks. 4. Patients with severe systemic illnesses. 5. Pregnant, planning pregnancy, or breastfeeding women of childbearing potential.

Design outcomes

Primary

MeasureTime frame
Changes in ISI,ESS and RIS.Timepoint: 4 Weeks

Secondary

MeasureTime frame
SF-12Timepoint: Baseline,4th week

Countries

India

Contacts

Public ContactProf Mohammad Shahid

State Takmeel Ut Tib College and Hospital Lucknow

prof.m.shahid@gmail.com8176900958

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026